Search

Search results

375 results found

Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.

Garg, Amit, Neeta Malviya, Andrew Strunk, Shari Wright, Afsaneh Alavi, Raed Alhusayen, Ali Alikhan, et al. 2022. “Comorbidity Screening in Hidradenitis Suppurativa: Evidence-Based Recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.”. Journal of the American Academy of Dermatology 86 (5): 1092-1101.

Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa.

Kimball, Alexa B, Murali Sundaram, Benjamin Banderas, Catherine Foley, and Alan L Shields. 2018. “Development and Initial Psychometric Evaluation of Patient-Reported Outcome Questionnaires to Evaluate the Symptoms and Impact of Hidradenitis Suppurativa.”. The Journal of Dermatological Treatment 29 (2): 152-64.

A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.

Palli, Ma Beatrice Alora, Claire Marie Reyes-Habito, Xinaida T Lima, and Alexa B Kimball. 2013. “A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of 3mg Drospirenone/0.02 Mg Ethinyl Estradiol Compared With Placebo in the Treatment of Moderate Truncal Acne Vulgaris.”. Journal of Drugs in Dermatology : JDD 12 (6): 633-7.